Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.

Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D'Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro

Journal: Critical reviews in oncology/hematology 2012;82(3):378-86

PMID: 21944842

Full Text on Elsevier Science View on PubMed

Abstract

Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice.

Address: Ospedale San Donato USL8, Medical Oncology, Department of Oncology, 52100 Arezzo, Italy. [email protected]

DOI: 10.1016/j.critrevonc.2011.08.005

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Benzenesulfonates, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Disease Management, Exanthema, Humans, Keratoacanthoma, Kidney Neoplasms, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Pruritus, Pyridines, Severity of Illness Index, Skin, Sorafenib